Disrupting Fear-based Memory Consolidation
This project represents a unique collaborative opportunity to pursue the essential proof-of-principle demonstration that non-invasive interference of sensory cortical memory consolidation shortly after an emotional experience can attenuate the cued fear response and potentially reduce the risk of developing post-trauma
| Condition(s) | Post-Traumatic Stress Disorder |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This project represents a unique collaborative opportunity to pursue the essential proof-of-principle demonstration that non-invasive interference of sensory cortical memory consolidation shortly after an emotional experience can attenuate the cued fear response and potentially reduce the risk of developing post-traumatic stress disorder (PTSD). If successful, the study results would anchor a potential advance in the treatment of patients after a traumatic event and seed future animal and clinical studies of emotional sensory cortical memory consolidation to reduce the prevalence and negative sequelae of PTSD. |
| Who can participate | Inclusion Criteria: * Ability to provide informed consent * Willingness to participate in study * No history of musculoskeletal impairment or neurological disease * Clinical diagnosis of PTSD for individuals in the PTSD group. Exclusion Criteria: * Any participant outside the age range * Participants that show signs of dementia (score \< 20 on the Montreal Cognitive Assessment) * Participants that have a history of major head trauma, a neurodegenerative disorder, or recent (\<6 months) substance abuse; * Participants that had a recent history of Central Nervous System (CNS) active drugs that may influence cortical excitability or learning; or * Participants that report contraindications to TMS or MRI - if participating in the TMS/MRI experiments * Current psychoactive medication usage * Cu |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Lead sponsor | Emory University |
| Locations | Atlanta, Georgia, United States; Atlanta, Georgia, United States |
| Start date | 2022-11-28 |
| NCT ID | NCT05560113 |
| Official listing | https://clinicaltrials.gov/study/NCT05560113 |